ArticleFrontiers in public health2025
Measuring success of targeted screening and prevention for hemoglobinopathies.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted screening for hemoglobinopathies is crucial for preventing affected births and mitigating the psychological and financial burdens on families. This study proposes two novel indicators-Screening index and prevention index-to evaluate the effectiveness of hemoglobinopathy prevention programs. The Screening index measures the proportion of at-risk women who are successfully screened and informed, while the Prevention Index assesses the number of women enrolled per birth prevented, reflecting the program's efficiency in reducing affected births. These indicators account for critical factors such as counselor quality, testing accuracy, timeliness, accessibility, and demographic influences, which impact program success. We also address the limitations of traditional measures and emphasize the need for normalized indicators to adjust for variations in carrier rates across different populations. This approach enhances program monitoring, informs resource allocation, and guides improvements in screening and prevention strategies. Through these measures, we aim to provide a clear understanding of program outcomes, highlight areas for improvement, and offer a cost-efficient approach to prevent hemoglobinopathy-related births.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.